Raunak Shrestha

University of California, San Francisco — United States

Medicine · Health Sciences

38h-index15.8kcitations276works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(141), Cancer, Lipids, and Metabolism(85), Cancer Genomics and Diagnostics(37), Immunotherapy and Immune Responses(26), Cancer Immunotherapy and Biomarkers(25)

Publications223 total

Supplementary Table 3. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Data 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 3. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 8. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 7. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Data 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 6. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 4. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Table 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 5. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Supplementary Table 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
2025Open Access
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
Nature Genetics·2025· 1 citedOpen Access
Extracellular vesicle-mediated delivery of CRISPR machinery silences androgen receptor in castration-resistant prostate cancer cells
Molecular Therapy·2025· 2 citedOpen Access
Genome-wide CRISPR screens identify PTGES3 as a novel AR modulator
2025Open Access
Abstract 1985: 5hmC-sequencing of matched cfDNA and tissue from men with mCRPC is concordant and identifies loss of AR signaling in NEPC and DNPC
Cancer Research·2025
Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
page 1 of 12Next →

Frequent Co-authors

Colin C. Collins(18), David A. Quigley(18), Martin Sjöström(17), Felix Y. Feng(17), Adam Foye(14), Eric J. Small(14), Meng Zhang(13), Rahul Aggarwal(13), Arian Lundberg(12), Ermin Hodzic(11), Joshi J. Alumkal(11), S. Cenk Şahinalp(10), Martin Gleave(10), Haolong Li(10), Alexander W. Wyatt(9), Jonathan Chou(9), Xiaolin Zhu(9), Lisa N. Chesner(9), Shawn Anderson(8), Anne Haegert(8)